The global generic drugs market is experiencing a structural decline, primarily driven by continuous price erosion and intensifying competition. According to Kunal Vora, Head of India Equity Research at BNP Paribas, this contraction has significant implications for Indian pharmaceutical companies, especially those heavily reliant on generic drug manufacturing.

Declining Opportunity in Generics

Vora points out that the revenue pool relevant to Indian generic drug makers has shrunk in recent years. The sector faces relentless pricing pressure, which squeezes margins and profitability. Additionally, companies must constantly innovate and replenish their product pipelines with new drug launches to sustain growth. While some blockbuster products, such as Revlimid, provided one-time revenue boosts for generics players, these opportunities are temporary and diminish unless newer drugs enter the off-patent phase.

The pipeline of innovator drugs going off-patent has been declining, reducing the number of lucrative generic licensing opportunities available. This creates a challenging environment for generic drug manufacturers, making it a “shrinking space,” as described by Vora.

Slowing Domestic Pharma Growth

While India’s domestic pharmaceutical market continues to grow, the pace has moderated from about 9-10% in earlier years to roughly 7% now. This slowdown further highlights the need for Indian pharma companies and investors to seek alternative growth avenues within the broader healthcare ecosystem.

Shift Towards Consumption-Led Healthcare Sectors

Given these headwinds, Vora emphasizes a strategic shift toward consumption-led healthcare segments, particularly diagnostics and private hospitals. These sectors benefit from factors such as:

• Rising affluence in India

• Increasing urban healthcare demand

• Growth in elective and diagnostic procedures

These segments offer more stable and sustainable growth prospects compared to generic pharmaceuticals, which are pressured by global pricing dynamics and patent cliffs.

Contract Development and Manufacturing Organizations (CDMO) Opportunity

The CDMO segment has garnered significant hype as a potential growth area. Many investors and analysts expected a shift of global pharmaceutical supply chains away from China, with Indian contract manufacturers positioned to benefit. However, Vora notes that the situation is still uncertain.

Some Indian companies, like Divi’s Laboratories, have indeed capitalized on this opportunity and delivered strong results. But a broad-based shift of supply chains to India remains unclear and may not happen at the scale initially anticipated. There is also a possibility that supply chains may return to the US or other regions, adding to the uncertainty.

Investment Recommendations

In light of these trends, Vora recommends focusing on companies with exposure to India’s growing healthcare consumption rather than global generics. He highlights Astral DM, a hospital chain, as a top mid-cap, high conviction idea. Astral DM is well placed to capitalize on urban healthcare demand and rising private healthcare penetration.

Why This Matters for Investors

The analysis by BNP Paribas reflects the changing dynamics within the pharmaceutical and healthcare sectors, particularly for India-focused investors:

• The generic drugs market is losing its appeal due to shrinking opportunities and pricing pressure.

• Investors may find better returns in healthcare segments driven by domestic consumption, such as diagnostics and private hospitals.

• The CDMO segment, though promising, carries uncertainty, and only select companies may benefit.

• Identifying strong mid-cap healthcare stocks like Astral DM could be a prudent strategy to capture India’s evolving healthcare growth story.

This comprehensive insight from BNP Paribas offers valuable guidance to investors and market participants looking to navigate the complexities of India’s healthcare sector amid global generic drug challenges and shifting market dynamics.

The Upcoming IPOs in this week and coming weeks are 3B Films, N R Vandana Tex Industries, Scoda Tubes,Neptune Petrochemicals, Astonea Labs, Nikita Papers, Prostarm Info Systems, Victory Electric Vehicles International, Blue Water Logistics, Wagons Learning.

The Current active IPO are Aegis Vopak Terminals, Schloss Bangalore, Unified Data - Tech Solutions.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.